The next chapter in the tale of Inotek Pharmaceuticals Corp. is all about “something strategic,” David Southwell, president and CEO, said after the phase II fixed-dose combination (FDC) trial of lead candidate trabodenoson and standard-of-care therapy latanoprost failed to move the needle in treating glaucoma.